Omeros (OMER) said Wednesday it has received an interim response from the US Food and Drug Administration on a dispute resolution request for narsoplimab...
Health care stocks remained marginally lower in late Friday trading, with the NYSE Health Care Index down about 0.7% and the SPDR Health Care Select Sector...
Health care stocks were broadly lower in early Friday afternoon trading, with the NYSE Health Care Index down 0.9% and the SPDR Health Care Select Sector...
Omeros (OMER) said Friday that OMS906 has obtained orphan drug designation from the Food and Drug Administration to treat the rare blood cell disease...
| Address | The Omeros Building Seattle, Washington 98119 |
| Phone | +1 206 676-5000 |
| Number of Employees | 236 |
| Recent SEC Filing | 08/09/2022 8-K |
| Chairman, President & Chief Executive Officer | Gregory A. Demopulos |
| Chief Financial Officer, Treasurer & VP | Michael A. Jacobsen |
| Chief Scientific Officer & Vice President-Science | George A. Gaitanaris |
| Chief Medical Officer & Vice President | J. Steven Whitaker |
| Price Open | $6.54 |
| Previous Close | $6.54 |
| 52 Week Range | $1.86 - 16.57 |
| Market Capitalization | $415.3 M |
| Shares Outstanding | 62.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 2.30 |
| Earnings per Share | -$1.78 |
| Beta vs. S&P 500 | N/A |
| Revenue | $29.9 M |
| Net Profit Margin | -503.94% |
| Return on Equity | 218.70% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
